How to get your head around optimal sequencing in RRMM?

Isabelle Vande Broek, MD, PhD 

 Vitaz, Sint-Niklaas, Hematologist,Department of Oncology & Hematology, Belgium

The treatment options in Myeloma have increased significantly over the last decade. Great news for patients and physicians but at the same time adding a lot of complexity in choosing the right therapy for a specific patient at a certain point in time. This e-learning module zooms in on treatment sequencing.

Approximate time: 1,5 hour

Course Content

Module 1: How to get your head around optimal sequencing in RRMM?

Accredited for 1 CME point

Start module 1

Inger Nijhof, MD, PhD 

Hematologist,

St. Antonius Hospital,

Department of Internal Medicine,

The Netherlands

Fredrik Schjesvold, MD, PhD 

Hematologist,

Oslo Myeloma Center,

Department of Hematology,

Norway

Isabelle Vande Broek, MD, PhD 

Hematologist,

Vitaz, Sint-Niklaas,

Department of Oncology & Hematology,

Belgium

Agoston Gyula Szabo , MD 

Hematologist,

Righospitalet Copenhagen,

Department of Hematology,

Denmark

Ville Varmavuo, MD, PhD 

Chief Medical Officer in Education,

Kotka,

Internal Medicine,

Finland

Prof. Xavier Leleu, MD, PhD 

Hematologist,

Academic Hospital of Poitiers,

France

Valdas Peceliunas, MD 

Hematologist,

Vilnius University Hospital Santaros Klinikos,

Department of Hematology,

Lithuania

Share this e-learning with your colleagues

Accreditation

Accreditation for this e-learning has been granted for 3 points by:

European Accreditation Council for Continuing Medical Education (EACCME)

Obtain CME points

To obtain CME points, you must answer at least 70% of the questions in the final test correctly. If you have a lower score, you can retake the final test twice more. You can pause the e-learning and then resume where you paused.

Clinical cases

Throughout the e-learning challenging clinical cases from daily practice are being presented by the International Expert Panel.

See all clinical cases